Why is Roivant Sciences stock surging today?

Shares of Roivant Sciences jumped 22.0% in pre-market trading after its Pulmovant unit announced positive topline data from the Phase 2 PHocus trial evaluating mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition for which there remains a considerable unmet need.

Results were presented by Professor Marc Humbert of Université Paris-Saclay, a recognized authority in pulmonary hypertension, at the European Respiratory Society International Congress 2026, adding significant scientific weight to the findings.

Reinforcing the momentum from the Phase 2 success, Roivant also announced that the Phase 3 PHrontier study of mosliciguat in PH-ILD has already begun with enrollment underway—a step indicating management's confidence in the results and shortening the pathway toward possible regulatory approval.

Mosliciguat is considered a potential first-in-class inhaled soluble guanylate cyclase activator, offering a distinct mode of action in a therapeutic area with scant treatment alternatives.

The company further held a dedicated investor call and webcast at 8:00 a.m. ET today to review the results, which added to the interest from institutional investors during pre-market trading.

This positive catalyst is part of a robust stretch of pipeline progress for Roivant. Its subsidiary Priovant secured FDA approval for LISRAYA (brepocitinib) for dermatomyositis in late August, signaling the company's transition into a commercial-stage biopharmaceutical firm.

The pre-market surge pushes ROIV far above its previous 52-week peak of $37.97, even as the broader market showed mixed performance—the NASDAQ was roughly unchanged while the S&P 500 and Dow Jones edged lower—highlighting that the stock's move was purely based on company-specific developments.

In combination, the favorable Phase 2 results, the fast transition to a Phase 3 trial, and the company's recent FDA approval momentum produced one of ROIV's biggest single-session jumps in recent memory, as investors reflected expectations of a significantly broadened addressable market across both its pulmonary and autoimmune franchises.

This story was generated with AI assistance and has been reviewed by an editor. For additional details, please refer to our Terms & Conditions.